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The dynamic, posttranslational modification of pro-
teins with a small ubiquitin-like modifier (SUMO) tag
has been recognized as an important cellular regula-
tory mechanism relevant to a number of cancers as
well as normal embryonic development. As part of a
program aimed toward the identification of inhibitors
of SUMO-conjugating enzymes, we developed a mi-
crofluidic electrophoretic mobility shift assay to
monitor sumoylation events in real time. We disclose
herein the use of this assay to identify a cell-perme-
able compound capable of blocking the transfer of
SUMO-1 from the E2 enzyme Ubc9 to the substrate.
We screened a small collection of compounds and
identified an oxygenated flavonoid derivative that
inhibits sumoylation in vitro. Next, we carried out an
in-depth mechanistic analysis that ruled out many
common false-positive mechanisms such as aggre-
gation or alkylation. Furthermore, we report that this
flavonoid inhibits a single step in the sumoylation
cascade: the transfer of SUMO from the E2 enzyme
(Ubc9) thioester conjugate to the substrate. In addi-
tion to having a unique mechanism of action, this
inhibitor has a discrete structure-activity relationship
uncharacteristic of a promiscuous inhibitor. Cell-
based studies showed that the flavonoid inhibits the
sumoylationof topoisomerase-I in response to camp-
tothecin treatment in two different breast cancer cell
lines, while isomeric analogs are inactive. Impor-
tantly, this compound blocks sumoylation while not
affecting ubiquitylation in cells. This work identifies
a point of entry for pharmacologic inhibition of the su-
moylation cascade and may serve as the basis for
continued study of additional pharmacophores that
modulateSUMO-conjugatingenzymessuchasUbc9.
INTRODUCTION
The small ubiquitin-like modifier, SUMO, is a protein tag that is
dynamically attached to and cleaved from lysines on protein604 Chemistry & Biology 20, 604–613, April 18, 2013 ª2013 Elseviersubstrates by a tightly regulated enzymatic cascade (Gareau
and Lima, 2010; Ulrich, 2009; Zhao, 2007). The modification of
proteins with a SUMO tag is a process that is critical to normal
development (Van Nguyen et al., 2012), and has been implicated
in a broad spectrum of disease states, most notably cancers
such as breast, colon, ovarian (Wang and Banerjee, 2004), and
multiple myeloma (Driscoll et al., 2010). High levels of SUMO-
conjugating enzymes, in particular Ubc9 (the sole SUMO E2
enzyme), have been associated with adverse clinical outcomes
for cancer patients and correlate with decreased survival rates
(Driscoll et al., 2010). Recently, sumoylation was also reported
as a requirement for Myc-driven tumorigenesis (Kessler et al.,
2012) and has been implicated as protective in the heat shock
response (Golebiowski et al., 2009). Enzymes in the SUMO
conjugation cascade are therefore of interest as drug targets.
Ubc9 has been discussed in the literature as a target (Duan
et al., 2009; Mo and Moschos, 2005), but there are no inhibitors
reported. In the case of the SUMO E1 enzyme, there are two
reported inhibitors known: ginkgolic acid (Fukuda et al., 2009a)
and kerriamycin B (Fukuda et al., 2009b).
The process of SUMO conjugation/deconjugation is often
described as an equilibrium and is biochemically analogous to
the process of protein ubiquitylation/deubiquitylation (Bedford
et al., 2011). The SUMO conjugation cascade involves E1 (acti-
vating), E2 (conjugating), andE3 (ligase) enzymes,while cleavage
is modulated by isopeptidases (referred to as SENPs or sentrin-
specific proteases). In this cascade, a SUMOconjugate is formed
by the generation of an isopeptide bond between a lysine on the
substrate and theC-terminal diglycine tail of SUMO.This process
is highly substrate-specific, and there is only one SUMO E2
enzyme (Ubc9) and 12 SUMO E3 enzymes in contrast to 40
ubiquitin E2 and 700 ubiquitin E3 enzymes (Cohen and
Tcherpakov, 2010). Given this disparity, it is not surprising that
while ubiquitin is estimated to modify 90% of the proteome, a
far smaller percentage of the proteome has been definitively
identified as a substrate for sumoylation (Golebiowski et al.,
2009). Sumoylation enzymes are also evolutionarily conserved,
with yeast and mammalian SUMO-conjugating enzymes dis-
playing high homology. From a structural standpoint, SUMO-1
shares a common fold with ubiquitin; however, it only has 18%
sequence homology. The other two SUMO homologs, SUMO-2
and -3, have roughly 50% sequence homology with SUMO-1
(but 95% homology with each other) (Mu¨ller et al., 2001).
The consequences of sumoylation are associated with
nuanced changes in protein structure, function, molecularLtd All rights reserved
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primarily associated with induced protein degradation and DNA
repair.Manydiscrete effects of sumoylation have been identified,
with examples occurring in the areas of transcriptional activation/
repression (Schmidt and Mu¨ller, 2003; Verger et al., 2003; Zhao,
2007), intracellular transport (Geoffroy et al., 2010; Majumdar
et al., 2011; Mu¨ller et al., 1998), DNA damage (Andrews et al.,
2005; Potts and Yu, 2005; Zhao and Blobel, 2005), chromosome
assembly (Chung et al., 2004), tumorigenesis (Kessler et al.,
2012; Wood et al., 2003), and stress response (Golebiowski
et al., 2009) as well as several others (Zhao, 2007). Recent work
suggests that the sumoylation response also acts synergistically
on groups of proteins with similar functions. This is particularly
evident in the DNA repair pathway, where sumoylation of several
proteins in the pathway leads to efficient repair, with individual
modifications having only a small effect (Psakhye and Jentsch,
2012). The specific effects of protein sumoylation remain an
active area of investigation. This effort is hampered by the obser-
vation that endogenous levels of sumoylation are quite low: less
than 1% of a substrate protein is estimated to be sumoylated at
any given time. The exception to this is RanGAP1, largely consid-
ered to be an atypical sumoylation substrate.
Despite reports suggesting that SUMO-conjugating enzymes
would likely be good drug targets (Mo andMoschos, 2005), there
is a lack of chemical probes to monitor and manipulate the pro-
cess of sumoylation. There are few biochemical assays available
to identify and evaluate small molecule inhibitors in these path-
ways, and the kinetic study of sumoylation remains nontrivial
(Alontaga et al., 2012). In the specific case of sumoylation, there
have only been two reports of small molecule inhibitors to date,
both of which appear to affect the E1 SUMO-activating enzyme
(SAE) (Fukuda et al., 2009a, 2009b). However, inhibitors of other
ubiquitin-like (UBL) signaling pathways have been identified as
well. To date, there have been a small number of prominent
successes of small molecule inhibitors of ubiquitin and NEDD8
E1 conjugation (Brownell et al., 2010; Lei et al., 2003; Soucy
et al., 2009; Ungermannova et al., 2012a, 2012b; Yang et al.,
2007; Zhong et al., 2012). There is also one notable example of
an ubiquitin E2 inhibitor in the literature (Ceccarelli et al., 2011).
Existing high throughput sumoylation assay technologies rely
on TR-FRET (Carlson et al., 2009) or electrochemiluminescence
approaches (Rouleau et al., 2008), which although robust use
heavily modified SUMO and substrate fusion proteins that are
substantially different from endogenous proteins and are not
suitable for all screening scenarios (such as natural product
extracts). An elegant method to identify natural product inhibi-
tors of sumoylation has also been reported, using image-based
analysis of a semi-intact cell system (Saitoh et al., 2006). This is a
unique and powerful approach, but appears to be somewhat
limited in throughput and is not appropriate to use for quantita-
tive kinetic analysis of inhibitors. Our goal was to overcome the
limitations of existing technologies and to develop an alternative,
highly quantitative sumoylation assay that would be useful for
screening large libraries (>100,000) of small molecules of diverse
origins, including natural product extracts as well as pure com-
pounds, enable the kinetic analysis of inhibitors, and minimize
false-positive results such as autofluorescent compounds.
In this study, we report the development of a sumoylation
assay that uses a microfluidic electrophoretic mobility shiftChemistry & Biology 20,system. This assay enables the real-time observation of the
sumoylation of a fluorescent peptide substrate in a reconstituted
biochemical cascade. Mobility shift assays are an example of a
medium throughput separation-based assay that utilizes differ-
ences of electrophoretic mobility in a capillary between the sub-
strate and product of an enzymatic reaction to directly monitor
product formation. This approach has several benefits, including
a highly quantitative kinetic or endpoint readout and a reduced
number of false-positive results generated by autoflourescent
compounds (Fanslau et al., 2010; Xiang et al., 2009, 2010). We
applied our assay to the kinetic screen of 600 small molecules
and natural product extracts and report the identification of a
flavonoid with potent SUMO inhibitory activity. A mechanistic
study reveals that this molecule functions by blocking the trans-
fer of SUMO-1 (and SUMO 2/3) from the E2-thioester complex to
a variety of substrates. This inhibitor displays a discrete struc-
ture-activity relationship and the ability to block a sumoylation
event in the context of whole cells. It does not appear to function
by aggregating, alkylating, or by generic mechanisms such as
membrane disruption or reacting with oxygen. This mechanisti-
cally unique small molecule is an example of a low molecular
weight inhibitor of the function of Ubc9, the sole SUMO E2
enzyme, and may provide the groundwork for future efforts to
target Ubc9 with small molecules.
RESULTS
Development of a Capillary Electrophoresis Assay
to Study Sumoylation Events
Because there are currently no such high throughput assays that
utilize single purified enzymes in the SUMO pathway (Alontaga
et al., 2012; Carlson et al., 2009), we turned to a reconstituted
biochemical cascade using recombinant SUMO-1, SUMO-
activating enzyme 1/2 (SAE-1/2, the SUMO E1 enzyme), and
Ubc9 (the SUMO E2 enzyme) proteins with a peptide substrate.
Importantly, this approach enables the assay to simultaneously
probe for inhibitors of both the E1 and E2 enzymes. E3 enzymes,
although important in vivo, are not necessary for in vitro sumoy-
lation systems and were not included. We were motivated by the
possibility that medium throughput electrophoretic mobility shift
technology could serve as a flexible and quantitative assay.
Furthermore, this approach has not been used for protein-based
posttranslational modifications such as ubiquitylation or sumoy-
lation previously.
Although the identification of sumoylation substrates remains
an active area of investigation, the majority of known substrates
contain the tetrapeptide consensus sequence cKxE/D, where c
is a hydrophobic amino acid, K is the lysine where the incipient
isopeptide bond is formed, x varies, and E/D is an acidic residue
(Rodriguez et al., 2001). Interestingly, the consensus sequence is
not an absolute requirement and discontinuous sumoylation
epitopes have also been observed (Pichler et al., 2005). With
this in mind, we synthesized a fluorescent 10-mer peptide
derived from the androgen receptor that contained the SUMO
consensus sequence IKLE (Figures S5 and S6 available online).
This polypeptide was modified at the N terminus with a fluores-
cent tag, 5-carboxyfluorescein (5-FAM), and is referred to as
FL-AR (Figure 1A). We exposed FL-AR to a mixture of recom-
binant SUMO-1, SAE 1/2, Ubc9, and ATP, and observed a604–613, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 605
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Figure 1. Development of an Electrophoretic Mobility Shift Assay for Protein Sumoylation
(A) Sequence and reactivity of a fluorescent polypeptide substrate for the sumoylation assay.
(B and C) In-gel fluorescence (B) and western blot (C) (with anti-SUMO-1 antibody) experiments showing the sumoylation of the fluorescent peptide.
(D) Separation of the substrate peptide and sumoylated product using the LabChip EZ Reader II system.
(E) Kinetic measurement of fluorescent peptide sumoylation. A sample from one 30 ml reaction mixture treated with 0.1%DMSO (either with or without Ubc9) was
analyzed using the LabChip EZ Reader II system every 4.88 min for 5 hr and percent conversion was monitored at each time point.
See also Figures S5 and S6.
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A Mechanistically Unique Sumoylation Inhibitortime-dependent accumulation of a single, higher molecular
weight fluorescent band as measured by in-gel fluorescence ex-
periments (Figure 1B). The molecular weight of the band was
consistent with a single SUMO-1 tag being attached to the
fluorescent peptide. Furthermore, western blot analysis with an
anti-SUMO-1 antibody (Figure 1C) confirmed that a SUMO-1
tag had in fact been attached to the fluorescent substrate.
We next moved to analyze the reaction by a mobility shift
protocol. We were pleased to find that under optimized separa-
tion conditions we could observe a near-baseline separation of
FL-AR and the SUMO-1-FL-AR (Figure 1D). Furthermore, the
accumulation of SUMO-1-FL-AR could be easily observed in
a time-dependent fashion, and the percent conversion could
be quantified using a ratiometric measurement of peak height
on an electropherogram (Figure 1D). Finally, miniaturization of
the assay was straightforward, with the assay performing
equally well in eppendorf tubes (250 ml total volume), 96-well
(100 ml total volume), and 384-well (20 ml total volume) formats.
Once optimized, we were able to obtain a separation-based
readout of reaction progress for a complete 384-well plate in
30 min by analyzing reactions that had been quenched
with EDTA.606 Chemistry & Biology 20, 604–613, April 18, 2013 ª2013 ElsevierOnce it was clear that an electrophoretic mobility shift assay
would be suitable for the detection of SUMO-1-FL-AR, wemoni-
tored product formation in kinetic mode. Use of the mobility shift
assay to measure sumoylation in real time was accomplished by
repeated analysis of a single 30 ml reaction mixture over the
course of 300 min. In this experiment, sumoylated product was
produced in a roughly linear scale over the first 100 min of
the reaction. In the absence of Ubc9, no conversion was
observed (Figure 1E). We also measured the IC50 of ginkgolic
acid, a previously reported inhibitor of SAE (Fukuda et al.,
2009a), by analyzing reactions that were quenched with EDTA
at the 90 min time point. The IC50 of ginkgolic acid was 9.1 mM,
comparable to the literature value of 3.0 mM (not shown).
A Kinetic Screen for Inhibitors of Sumoylation
As part of our interest in screening natural products, we initially
evaluated a well-characterized plate of 80 extracts. This plate
was assembled to include commonly problematic extracts with
autofluorescence, high salt, polyphenols/tannins, and high
viscosity. Of the 80 samples on this plate, nine showed inhibitory
activity in our assay. We were pleased to find that none of the
nine were autofluorescent. However, taxonomic investigationLtd All rights reserved
Figure 2. Ten Most Active Compounds from the Kinetic Screen
GA30 = Ginkgolic acid C15, 30 mM. All other compounds are assayed at 5 mM.
The sumoylation reaction was performed for 90 min at room temperature, and
the reaction was quenched by the addition of EDTA. Percent conversion was
measured using the LabChip EZ Reader II system as described in the
Experimental Procedures. Percent conversion is normalized to a DMSO-
treated control sample in which percent conversion is 100. Values represent
the mean of three replicates; error bars represent 1 SD from the mean.
See also Figures S7 and S8.
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A Mechanistically Unique Sumoylation Inhibitorof the active extracts indicated that seven extracts were from
known producers of polyphenols/tannins. Because we were
concerned that this type of molecule might be broadly interfering
with our assay system,we next performed a kinetic screen of 500
flavonoids, chalcones, and related polyphenolic compounds in
the electrophoretic mobility shift assay (Figures S7 and S8).
For this kinetic screen, 20 ml reaction mixtures in 384-well plates
were dosed with inhibitors at 30 mM (roughly comparable to the
concentration expected in extracts) and initiated with ATP. After
incubating for 30 minutes at room temperature, samples from
each well were analyzed every 15 min. Conversion to the
sumoylated product was monitored using the LabChip EZ
Reader II system for four to five time points for each sample,
for a total reaction time of 90–120 min. In this method (using a
12-sipper chip), 12 samples including a DMSO control, ginkgolic
acid (a positive control of inhibition), and ten test compounds
weremonitored simultaneously (see Supplemental Experimental
Procedures). By slightly offsetting analysis times, 80 compounds
were kinetically screened in each experiment and a total of 500
compounds were screened in seven separate experiments.
We were encouraged to find that of the 500 pure compounds
screened, only ten compounds showed greater than 90% inhibi-
tion after 100 min. We re-assayed all ten compounds at a lower
concentration of 5 mM in an effort to distinguish more potent
compounds. At this concentration, a clear distinction could be
made among the different compounds, with the most potent
compound being 2-D08 (20,30,40-trihydroxyflavone) (Figure 2). A
number of other synthetic and natural polyhydroxylated flavo-
noids proved to be slightly less active. Both the C15 and C17
analogs of ginkgolic acid were evaluated and proved to be
slightly less potent.
In an effort to further evaluate the properties of 2-D08, we next
performed a more in-depth biochemical analysis. The IC50 for
2-D08 in this assay was 6.0 ± 1.3 mM (Figure 3A). We then eval-
uated the ability of 2-D08 to inhibit the sumoylation of fully intact
recombinant IkBa, a well-studied sumoylation substrate (Des-
terro et al., 1998). Western blot analysis of in vitro sumoylation
experiments showed that 2-D08 exhibited a dose-dependent
inhibition of the SUMO-1 modification of recombinant IkBa (Fig-
ure 3B). This inhibition occurred in a concentration range consis-
tent with the IC50 measured in the screening assay. Furthermore,
2-D08 also inhibited the conjugation of SUMO-2 (Figure 3C) and
SUMO-3 (Figure 3D) to IkBawithin a similar concentration range.
Structure-Activity Relationship and Mechanism of
Action
We next evaluated a series of compounds closely related to
2-D08 and evaluated them in the sumoylation assay. Interest-
ingly, a discrete SAR was observed (Figure 4). Small deviations
from the core structure of 2-D08 resulted in a substantial loss
of inhibitory activity. While 2-D08 displayed 90% inhibition at
30 mM, the permethylated derivative 1 exhibited only 4% inhibi-
tion. Themeta- and para- isomers 2 and 3were substantially less
active at 21% and 4% inhibition, respectively. Because a strict
requirement for an ortho- substituent could be indicative of a
nonplanar pharmacophore, we synthesized two other analogs
containing chloro (7) and methyl (6) substituents in the ortho-
position (see Supplemental Experimental Procedures) and eval-
uated compounds without a phenol (8). These compoundsChemistry & Biology 20,displayed markedly decreased inhibition, indicating that the
phenol functionality is a requirement. Similarly, other similar
compounds (4, 5, 10, 11) also exhibited a substantial loss of
activity, while other catechols retained some activity (Figure 2).
Having established an initial structure-activity relationship for
2-D08, we next moved to study its mechanism of action. Our
initial screening assay involved a reconstituted sumoylation
cascade, including recombinant SAE 1/2, Ubc9, and SUMO-1.
To evaluate whether 2-D08 inhibited individual steps in the
cascade, we utilized a fluorescently labeled SUMO-1 (referred604–613, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 607
Figure 3. Potency and Selectivity of 2-D08
(A) IC50 for 2-D08 is measured to be 6.0 mM using the mobility shift assay.
Reactions were performed at varying concentrations of 2-D08 and quenched
with EDTA after 90 min. Conversion was measured using the Caliper EZ
Reader II system. Values represent the mean of three replicates; error bars
represent 1 SD from the mean.
(B–D) 2-D08 dose-dependently inhibits the sumoylation of IkBa with SUMO-1
(B), SUMO-2 (C), and SUMO-3 (D) as observed by western blot using anti-IkBa
(C-21) antibody. Sumoylation of full-length protein IkBa (human, recombinant)
was performed with recombinant SUMO-1, SUMO-2, or SUMO-3 in the
presence/absence of 2-D08 at room temperature for 90 min and sumoylated
IkBa level was measured by western blot analysis with an anti-IkBa antibody.
See also Figures S1 and S2.
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A Mechanistically Unique Sumoylation Inhibitorto as FL-SUMO-1) (Alontaga et al., 2012), rather than a fluores-
cent substrate. Straightforward gel shift experiments clearly
indicated the activation and transfer of SUMO-1 between the
enzymes. In the presence of FL-SUMO-1, SAE 1/2, and ATP,
clean conversion to the SAE-(FL-SUMO-1) thioester complex
was observed. Treatment with ginkgolic acid (an inhibitor of
SAE) inhibited this process,while 2-D08hadno effect (Figure 5A).
This indicated that while ginkgolic acid inhibited E1 activation,
2-D08 did not. In the presence of FL-SUMO-1, SAE 1/2, Ubc9,
and ATP, but no peptide substrate, formation of the Ubc9-(FL-608 Chemistry & Biology 20, 604–613, April 18, 2013 ª2013 ElsevierSUMO-1) thioester was also observed. Again, ginkgolic acid
cleanly blocked this process while 2-D08 had no effect (Fig-
ure 5B). In a third experiment, where an intact cascade
comprised of FL-SUMO-1, SAE 1/2, Ubc9, and ATP were com-
bined with an unlabeled protein substrate, 2-D08 cleanly
inhibited formation of the product (Figure 5C; Figures S10 and
S11). These data clearly indicate that 2-D08 inhibits the transfer
of SUMO-1 from the E2 thioester to the SUMOsubstrate, without
disrupting any of the other individual steps in the biochemical
cascade.
Inhibition of Sumoylation in Cancer Cell Lines
Sumoylation has been shown to modulate a diverse variety of
cellular phenomena. A particularly important role for sumoylation
has been in DNA repair, whereby sumoylation of repair enzymes
results in changes in their function and subcellular localization
and other consequences. A specific example is the observation
that treatment of cells with camptothecin (CPT) resulted in the
rapid accumulation of sumoylated topoisomerase I (topo-I)
(Desai et al., 2001; Mao et al., 2000). This effect has also been
replicated in vitro. Although the consequences of this accumula-
tion are complex and not well understood, high levels of sumoy-
lation of topo-I appear to be at least one mechanism leading to
CPT resistance. This observation is supported by experiments
showing that cells overexpressing SUMO have an increased
resistance to CPT (Yang et al., 2006).
To study the effects of 2-D08 on topo-I, we first confirmed that
2-D08 inhibited the sumoylation of a topo-I fragment in vitro (Fig-
ure 6A). 2-D08, but not the closely related meta- and para-
analogs 2 and 3, inhibited the sumoylation of the topo-I fragment
at a concentration of 30 mM using a reconstituted sumoylation
cascade. We next moved to evaluate the sumoylation of topo-I
in intact ZR-75-1 cells and in BT-474 cells, breast cancer cell
lines where the sumoylation of topo-I has been observed previ-
ously (Desai et al., 2001). After 15 min of treatment with CPT,
an accumulation of topo-I-SUMO conjugates was observed in
both cell lines. However, when cells were pretreated with
2-D08 for several hours, this effect was inhibited. Critically, the
meta- and para- analogs 2 and 3 were completely inactive in
cells at the same concentration, again highlighting the specificity
of this effect (Figures 6B and 6C; Figure S9).
Finally, we performed a ubiquitylation assay to see if 2-D08
affects protein ubiquitylation in cells. In BT-474 cells treated
with MG-132, a proteasome inhibitor, accumulation of high
molecular weight ubiquitylated adducts could be observed by
western blot. In the presence of 2-D08 andMG-132, no inhibition
of this process was observed. In contrast, when cells were
treated with both PYR-41 (a known ubiquitylation inhibitor)
(Yang et al., 2007) andMG-132 (a proteasome inhibitor) (Tsubuki
et al., 1996), the ubiquitin conjugates were substantially de-
creased, indicating that while PYR-41 inhibits ubiquitylation,
2-D08 does not (Figure 6D).
DISCUSSION
Protein sumoylation continues to raise interest as a key regulator
of intracellular events and as a driver of several human cancers.
The ability to perturb specific steps within the sumoylation cycle
would be invaluable in developing our understanding of the rolesLtd All rights reserved
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Figure 4. Structure-Activity Relationship of 2-D08
Sumoylation reactions were performed for 2 hr at room temperature, and then were quenched by the addition of EDTA. Percent conversion was measured using
the LabChip EZ Reader II system as described in the Experimental Procedures. Percent conversion is normalized relative to a DMSO-treated control sample in
which percent conversion is 100. Values represent the mean of three replicates; error bars represent 1 SD from the mean.
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A Mechanistically Unique Sumoylation Inhibitorof conjugating enzymes in cellular homeostasis as well as dis-
ease states and could lead to a new approach to cancer chemo-
therapy. In this report, we describe a sumoylation assay that
relies on electrophoretic mobility shift technology. Furthermore,
we show that this assay is useful in a kinetic screen to identify
mechanistically novel, cell-permeable small molecules capable
of inhibiting single steps within the biochemical cascade. An
active molecule identified from this screen (2-D08) does not
block the formation of the Ubc9-SUMO thioester, but prevents
transfer of the SUMO tag to a number of substrates. Further-
more, we show that the newly identified inhibitor is capable of
blocking the sumoylation of topo-I in response to CPT treatment
in the context of two different breast cancer cell lines. Finally, it
does not inhibit the global ubiquitylation increase in response
to proteasome inhibition, indicating pathway selectivity. This
molecule may provide an inroad for the pharmacological pertur-
bation of the SUMO pathway.
A variety of flavonoids closely related to 2-D08 have been
studied in several biological contexts. 2-D08 is a synthetic
flavone that has been reported in studies evaluating radical
scavenging (Cotelle et al., 1992; Seyoum et al., 2006), antioxi-
dant (Cotelle et al., 1996), and antimutagenic (Laget et al.,
1995) effects. Although 2-D08 has been studied in several other
systems, activity profiles in these reports do not correlate with
observations made here. In these previous studies, 2-D08 isChemistry & Biology 20,not the most potent compound and is often substantially less
potent than other molecules studied. As one specific example,
2-D08 and the 7,8-dihydroxyflavone 8 display nearly identical
radical formation activities (Seyoum et al., 2006), while they
exhibit markedly different activities in the sumoylation assay
with no detectable effect for 8 in the biochemical assay. The
lack of correlation with other reported activities indicates that
the effects we observe in both biochemical and cell-based
assays are not a result of these other mechanisms.
Importantly, 2-D08 appears to act in the present context by a
biochemical inhibition of protein function, rather than by a
physiochemical function (for example, such as by nonspecific
cysteine alkylation, reaction with oxygen, or aggregation). This
observation is supported by our experiments showing that
2-D08 still inhibits SUMO conjugation in the presence of deter-
gents such as Triton X-100 or CHAPS (Figure S1; aggregation
is not present in either case as measured by dynamic light scat-
tering; Figures S3 and S4), or in the presence of catalase to
degrade hydroperoxide adducts (Figure S2) (Tjernberg et al.,
2004) (see Supplemental Experimental Procedures for details).
Additionally, modifications that make 2-D08 more hydrophobic,
which should increase aggregation in aqueous medium, result in
a decrease in activity. Furthermore, 2-D08 is active independent
of thiol concentration: our assay is conducted at a relatively high
concentration of DTT (1 mM), and 2-D08 is equally active at this604–613, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 609
Figure 5. Mechanism of Action of 2-D08
Using a Fluorescently Labeled SUMO-1
(A) Ginkgolic acid, but not 2-D08, inhibits E1-
SUMO-1 thioester formation.
(B) Ginkgolic acid, but not 2-D08, inhibits Ubc9-
SUMO-1 thioester formation. For thioester bond
formation assays under non-reducing condition,
reaction mixtures were incubated for 37C for
20 min in the absence of DTT, and thioester bond
formation was detected by in-gel fluorescence
imaging. For thioester bond formation assay under
reducing conditions, see Figures S10, S11 and the
Supplemental Experimental Procedures.
(C) Both ginkgolic acid and 2-D08 inhibit the
sumoylation of IkBa. Sumoylation reactions were
performed with full-length protein IkBa and SUMO-
1-Fluorescein at room temperature for 90 min, and
then sumoylated protein level was detected by
in-gel fluorescence imaging.
See also Figures S3 and S4.
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that nonspecific thiol alkylation is not a mechanism for inhibition
in this assay. We have observed that 2-D08, but not isomeric
analogs, inhibits sumoylation events in response to stimuli in
several breast cancer cell lines. Furthermore, 2-D08 inhibits
SUMO conjugation but not global ubiquitylation, indicating that
it is not a pan-E2 inhibitor and exhibits pathway specificity. It is
clear that 2-D08 is a sumoylation inhibitor and not a ubiquityla-
tion inhibitor. However, we cannot rule out at this time that
2-D08 may have activity on pathways other than the sumoyla-
tion/ubiquitylation processes that may or may not be related in
more complex cell-based contexts. This study shows that the
electrophoretic mobility shift assay can be used to identify cell-
permeable sumoylation inhibitors that are mechanistically
analyzed in a straightforward manner. Furthermore, this work
indicates that the biochemical blockade of SUMO transfer from
Ubc9 to the substrate is a step that should be evaluated further
for the pharmacologic inhibition of sumoylation and the study of
more drug-like sumoylation inhibitors as anticancer compounds.
Our future work includes the screening of a large and diverse
library of compounds for the identification of more potent and/
or structurally and mechanistically unique inhibitors of protein
sumoylation.610 Chemistry & Biology 20, 604–613, April 18, 2013 ª2013 Elsevier Ltd All rights reservedSIGNIFICANCE
Despite the discovery that protein
sumoylation plays a critical role in the
growth of cancer cells (notably Myc-
driven tumorcell lines) and isassociated
with adverse clinical outcomes, few
smallmolecule inhibitorsof thisprocess
exist. To address this, we have devel-
oped an electrophoretic mobility shift
assay suitable for medium throughput
analysis of compound libraries. Further-
more, we have identified a sumoylation
inhibitor. This report presents an ex-
ample of a cell-permeable small mole-
cule capable of blocking SUMO transferfrom the Ubc9-thioester complex to a variety of substrates.
In addition to the consensus sequence-containing peptide
initially used in the assay, sumoylation of a fully intact protein
substrate (IkBa) and a fragment of topo-I were also inhibited.
This activity was identified using an in vitro approach; how-
ever, we were also able to observe blockade of an induced
sumoylation event in intact cells as well. We were able to
show the inhibition of topo-I sumoylation in cancer cells
and that global ubiquitylation remained unaffected, indi-
cating that 2-D08 is a pathway-specific inhibitor. Ubc9, the
sole SUMO E2 enzyme, is an important cancer target, and
the results described herein demonstrate that further inves-
tigation of molecules that inhibit this step in the process of
SUMO conjugation is warranted. Future work will focus on
the continued use of the mobility shift assay for the identifi-
cation, optimization, and in-depth study of more potent
pharmacophores that have this uniquemechanismof action.EXPERIMENTAL PROCEDURES
Reagents, Proteins, and Cells
Adenosine 50-triphosphate (ATP) magnesium salt, DL-dithiothreitol (DTT), and
ginkgolic acid (C17:1) were purchased from Sigma-Aldrich. Ginkgolic acid
Figure 6. 2-D08 Inhibits the Sumoylation of Topoisomerase-I in
Response to Camptothecin Treatment
(A) 2-D08, but not the inactive meta- or para- isomers 2 or 3, inhibits the
sumoylation of a Topo-I fragment.
(B) 2-D08 but not the inactive meta- or para- isomers 2 or 3, inhibits Topo-I
sumoylation in ZR-75-1 cells.
(C) 2-D08, but not the inactive meta- or para- isomers 2 or 3, Inhibits Topo-I
sumoylation in BT-474 cells.
(D) Treatment of BT-474 cells with MG-132 results in an increase in high
molecular weight ubiquitylated proteins relative to a DMSO control. In MG-
132-treated BT-474 cells, PYR-41 inhibits global ubiquitylation, but 2-D08
does not. Concentration of compounds: 2-D08, 100 mM; compound 2, 100 mM;
compound 3, 100 mM; CPT, 10 mM; PYR-41, 50 mM; MG-132, 10 mM.
See also Figure S9.
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Chemistry & Biology 20,(C15:1) was purchased from EMD Millipore. Library of 500 flavones was
purchased from TimTec LLC and INDOFINE Chemical Company. The
following recombinant proteins were purchased and used without further
purification: SUMO E1 (E-315, Boston Biochem), GST-SUMO E1 (E-310,
Boston Biochem), Ubc9 (BML-UW9320, Enzo Life Sciences), SUMO-1
(N-terminal His6-tag, BML-UW9195, Enzo Life Sciences), SUMO-2 (1-93,
ALX-201-089-C500, Enzo Life Sciences), SUMO-3 (1-92, ALX-201-087-
C500, Enzo Life Sciences), IkBa (untagged, BML-UW9975, Enzo Life
Sciences), Topoisomerase I fragment (1-200, B007, LAE Biotech), SUMO-1
Fluorescein (UL-735, Boston Biochem). ZR-75-1 and BT-474 breast cancer
cells were obtained from American Type Culture Collection (ATCC).
Sumoylation Assay: General Procedure
The in vitro sumoylation assay was performed in 20 ml Tris buffer (50 mM Tris
pH 9.0, 5 mM MgCl2, 1 mM DTT and 2 mM ATP) with SUMO E1 (0.1 mM),
SUMO-1 (His-tag, 1.4 mM), Ubc9 (0.25 mM), and a fluorescent peptide FL-AR
(1.0 mM). The reaction was initiated by the addition of ATP (final concentration
of ATP = 2 mM). After incubation for 90 min at room temperature, samples
were mixed with NuPAGE LDS sample buffer (Invitrogen) or Laemmli sample
buffer (Bio-Rad), the resulting mixtures were boiled for 5 min, and then
SUMOylation level was measured by in-gel fluorescence imaging or western
blot. Alternatively, the sumoylation assay was performed using IkBa
(0.35 mM) or topoisomerase I fragment (1–200) (0.25 mM) as SUMO substrates
instead of the fluorescent peptide FL-AR and their sumoylation level was
measured by western blot.
Thioester Bond Formation Assays
The E1-SUMO1 thioester bond formation assay was performed in 20 ml Tris
buffer (50 mM Tris pH 8, 5 mM MgCl2, and 2 mM ATP) with GST-SUMO E1
(E-310, 0.35 mM) and SUMO-1 Fluorescein (0.5 mM) in the absence or presence
of 1 mM DTT. After incubation for 20 min at 37C, samples were loaded on a
Criterion Tris-HCl Precast Gel (Bio-Rad) and resolved by electrophoresis.
E1-SUMO1 thioester bond formation was detected by in-gel fluorescence
imaging.
Ubc9-SUMO1 thioester bond formation assay was performed with E1
(E-315, 0.10 mM), Ubc9 (0.70 mM), and SUMO-1 Fluorescein (0.50 mM) in the
absence of DTT. After incubation for 20 min at 37C, a set of samples were
mixed with SDS sample buffer without DTT. Another set of samples were
mixed with SDS sample buffer with DTT (150 mM) and boiled for 5 min.
Samples were loaded on a Criterion Tris-HCl Precast Gel (Bio-Rad) and
resolved by electrophoresis. Ubc9-SUMO1 thioester bond formation was
detected by in-gel fluorescence imaging.
Western Blots
Samples were loaded on Criterion Tris-HCl precast gels (Bio-Rad), resolved by
electrophoresis and transferred to a nitrocellulose membrane (Whatman,
Protran BA85). Membranes were blocked with 5% nonfat dry milk (Bio-Rad)
for 1 hr, and incubated with a primary antibody in Tween buffer (5 mM Tris,
2.5 mM EDTA, 50 mM NaCl, 0.1% Tween 20) for 1 hr at room temperature.
Membrane was washed with Tween buffer and incubated with an HRP-
conjugated secondary antibody for 1 hr at room temperature. After washing
membrane, the blot was visualized using the ECL system on BioMax MR
film (Eastman Kodak). The following antibodies were used for western blot:
anti-SUMO-1 (CT, Enzo Life Sciences, 1:1,500 dilution), anti-Topo I (H-5,
Santa Cruz biotechnology, 1:1,500 dilution), anti-Topo I (F14, LAE Biotech
International, 1:1,500 dilution), anti-IkBa (C-21, Santa Cruz biotechnology,
1:1,000 dilution), anti-ubiquitin (P4D1, Santa Cruz biotechnology, 1:1,000
dilution), anti-actin (C4, EMD Millipore, 1:3,000 dilution), HRP-conjugated
goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, 1:5,000 dilu-
tion), and HRP-conjugated goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories, 1:5,000 dilution).
Topo I Sumoylation in Cancer Cells
ZR-75-1 and BT-474 breast cancer cells were cultured at 37C in RPMI 1640
medium (Mediatech) with 10% fetal bovine serum (FBS, Mediatech) and 1%
antimycotic-antibiotic (Mediatech, Inc.). Cells were treated with DMSO or
the corresponding compound for 6 hr, followed by treatment with campto-
thecin (Selleck Chemicals) for 15 min. The SUMOylated Topo I level was604–613, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 611
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A Mechanistically Unique Sumoylation Inhibitormeasured by western blot according to procedures reported in the literature
(Desai et al., 2001; Mao et al., 2000).
Ubiquitination in Cancer Cells
BT-474 cells were treated with DMSO, 2-D08 or PYR-41 (Sigma-Aldrich) in the
absence/presence ofMG-132 (Santa Cruz) for 6 hr at 37C. Cells were washed
with PBS, lysed in SDS lysis buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10%
glycerol) on ice, and boiled for 5 min. Equal amounts of proteins from each
sample were mixed with SDS sample buffer and boiled for 5 min. Western
blot was carried out and the ubiquitinated protein level was measured using
anti-ubiquitin (P4D1) antibody.
In-Gel Fluorescence Imaging
Samples were loaded on Criterion Tris-HCl precast gels (Bio-Rad) and
resolved by electrophoresis. In-gel fluorescence images were obtained by
UVP MultiDoc-It imaging systems (Ultra-Violet Products), and images were
analyzed using UVP Doc-It LS image analysis software (Ultra-Violet Products).
Sumoylation Electrophoretic Mobility Shift Assay
The in vitro sumoylation assay was carried out as described in the general
procedure above in 384-well plate format. After the desired reaction time,
EDTA (0.25 M, 10 mL) was added to each well instead of sample buffer to
quench the reaction. Samples were analyzed using a LabChip EZ Reader II
(Caliper Life Sciences) and run conditions were: upstream voltage of 2500
V, downstream voltage of 500 V, and pressure of 1.0 psi. Percent conver-
sion is defined as 100 3 P/(P+S), where P and S are peak heights of sumoy-
lated product SUMO-1-FL-AR and peptide substrate FL-AR, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and 11 figures can be found with this article online at http://dx.doi.org/10.
1016/j.chembiol.2013.04.001.
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